Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Roche, Garvan Institute Epigenomic Partnership

Published: Wednesday, August 20, 2014
Last Updated: Wednesday, August 20, 2014
Bookmark and Share
Roche and the Garvan Institute of Medical Research today announce a collaboration to develop new technologies for targeted epigenomic analysis using DNA sequencing.

Genomics is a rapidly evolving field with a focus on realizing the potential use of sequencing information in patient diagnosis and treatment.  More recently, epigenetics - the heritable changes in gene expression that are not caused by changes in the DNA sequence or genetic code, but rather involve secondary chemical modifications of the DNA and the structural proteins in chromosomes - is being recognized as playing an important role in a host of biological processes and their role in cancer has been increasingly investigated.  Due to the myriad of epigenomic events responsible for influencing expression of genes in chromosomes, more advanced methods are being sought to accurately analyze these changes.

Under the terms of the two-year discovery agreement, the Garvan Institute and Roche will collaborate to develop new methods to accurately analyze regions of the epigenome. The collaboration brings together the world-leading genomics expertise and infrastructure at the Garvan Institute and the best-in-class products for target enrichment from Roche NimbleGen, part of the Roche Sequencing Unit. As part of the agreement, the SeqCap Target Enrichment System from Roche will be used by scientists at the Garvan Institute to further their research in epigenetic influences on human diseases.

“This is an excellent example of collaboration between a leading edge company and research institute in the development of advanced technology for genetic analysis, which will empower more research into human biology and disease, and lead to many translational opportunities,” said Professor John Mattick, Executive Director of the Garvan Institute.

 “In addition to our recent investments in sequencing platform technologies,  our research team is  working closely with key opinion leaders to advance sequencing applications of current and future technologies,” said Tom Albert, Head of Research at Roche’s Sequencing Unit.  “This collaboration with the Garvan Institute illustrates the potential of SeqCap Target Enrichment products in additional sequencing applications for epigenetic research. This brings us closer to delivering sequencing applications to the clinic that offer truly differentiated medical value.”

Financial terms of the collaboration are not disclosed.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Roche Introduces Enhanced Whole Exome Sequencing Solution
The company has announced the launch of the SeqCap EZ MedExome Target Enrichment Kit1.
Wednesday, September 23, 2015
Roche Invests For The Future In Its Basel Site
Investments of 3 billion Swiss francs in modern research infrastructure, attractive workplaces and sustainable site development.
Thursday, October 23, 2014
Roche, Oryzon Announce Epigenetics Collaboration
Collaboration spans research, development and commercialization of LSD1 inhibitors for oncology, haematology and non-malignant conditions.
Monday, April 07, 2014
Roche 454 Sequencing Systems Successfully Resolve Genetic Mutations in Blood Cancer Cases
International study presented at ASH Meeting demonstrates the potential of 454 Sequencing Systems to comprehensively characterize an individual’s blood cancer type to guide personalized therapy decisions.
Thursday, December 13, 2012
Roche and Agilent to Provide Continued Service and Support to Roche NimbleGen Microarray Customers
Transition of services beginning immediately.
Wednesday, November 07, 2012
Roche's Troponin T Nominated for International Inventor Award
European Patent Office nominates the team of Klaus Hallermayer from Roche Penzberg, jointly with Prof. Hugo Katus from the University of Heidelberg.
Monday, June 11, 2012
Roche and Life Technologies Corporation Sign New PCR IVD Licenses
Companies announced that they have entered into two license agreements to allow LTC to expand its PCR offerings for diagnostics applications.
Thursday, February 23, 2012
Roche and Labcyte Integrate Echo and LightCycler Systems to Increase Performance of qPCR-based RNA/DNA Analyses
Companies cooperate around high-speed, miniaturized quantitative PCR (qPCR) to monitor the expression of tens to thousands of genes for therapeutic research.
Wednesday, December 07, 2011
Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
Roche NimbleGen, Inc. and BGI, a large genomic organization, announced that they have developed a Major Histocompatibility Complex (MHC) region capture technology for Human Disease and Biomedical Research.
Tuesday, November 29, 2011
Complete Genome of Cynomolgus Monkey and Novel Gene Expression Microarray for Drug Safety Assessment
A team of researchers from Roche have generated the first draft genome sequence of the cynomolgus monkey and developed a novel microarray design for in depth expression profiling for use in preclinical drug safety research.
Thursday, September 22, 2011
Roche Buys Full Rights to Danoprevir from InterMune
Agreement reinforces Roche’s leadership in the fight against hepatitis C.
Wednesday, October 13, 2010
Roche and reMYND Enter Agreement to Develop First-in-Class Disease-Modifying Treatments for Parkinson’s and Alzheimer’s Disease
Novel therapies to target unmet needs in neurodegenerative disorders.
Tuesday, September 07, 2010
Macrogen, Inc. Certified as NimbleGen Array Service Provider for Korea
Macrogen has been certified to process customer samples for NimbleGen CGH/CNV services in their lab in Seoul.
Wednesday, July 14, 2010
Roche and Google.org Start Initiative for Early Discovery of New Diseases
The joint project is aimed to demonstrate the feasibility of developing a multidisciplinary surveillance, research and response system.
Wednesday, July 29, 2009
Roche Applied Science Opens Application Support Center in Shanghai
The new Application Support Center will apply broad range of technologies to a diverse range of life science research topics.
Friday, May 29, 2009
Scientific News
Genetic Risk Factors of Disparate Diseases Share Similar Biological Underpinnings
Penn Institute for Biomedical Informatics and colleagues identify "roadmap" of disease mechanisms to identify candidate drug targets.
Childhood Asthma Research Receives $2M
Research into the impact of a child’s upbringing and social and physical environments on the development of asthma will receive $2 million to tackle the condition that affects as many as one in three Canadians.
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Genetic Markers Influence Addiction
Differences in vulnerability to cocaine addiction and relapse linked to both inherited traits and epigenetics, U-M researchers find.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Fructose Alters Hundreds of Brain Genes
UCLA scientists report that diet rich in omega-3 fatty acids can reverse the damage.
DNA Barcodes Gone Wild
A team of researchers at University of Toronto’s Donnelly Centre and Sinai Health System’s Lunenfeld-Tanenbaum Research Institute (LTRI) has developed a new technology that can stitch together DNA barcodes inside a cell to simultaneously search amongst millions of protein pairs for protein interactions.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!